Τίτλος:
Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When DM and hypertension coexist, they constitute a dual cardiovascular threat and should be adequately controlled. Novel antihyperglycemic agents, including sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been used in the treatment of DM. Beyond their glucose-lowering effects, these drugs have shown beneficial pleiotropic cardiovascular effects, including lowering of arterial blood pressure (BP), as acknowledged in the 2019 European Society of Cardiology/European Association for the Study of Diabetes guidelines on diabetes, prediabetes, and cardiovascular diseases. The purpose of this review was to summarize the available information on the BP-reducing effects of these new glucose-lowering drug classes and provide a brief report on underlying pathophysiological mechanisms. We also compare the three drug classes (SGLT-2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors) in terms of their BP-lowering effect and show that the greater BP reduction seems to be achieved with SGLT-2 inhibitors, whereas DPP-4 inhibitors have probably the mildest antihypertensive effect. © 2020, Springer Nature Switzerland AG.
Συγγραφείς:
Liakos, C.I.
Papadopoulos, D.P.
Sanidas, E.A.
Markou, M.I.
Hatziagelaki, E.E.
Grassos, C.A.
Velliou, M.L.
Barbetseas, J.D.
Περιοδικό:
American Journal of Cardiovascular Drugs
Λέξεις-κλειδιά:
albiglutide; alogliptin; anagliptin; canagliflozin; dapagliflozin; dipeptidyl peptidase IV inhibitor; dulaglutide; empagliflozin; ertugliflozin; exendin 4; glucagon like peptide 1 receptor agonist; ipragliflozin; linagliptin; liraglutide; lixisenatide; luseogliflozin; saxagliptin; semaglutide; sitagliptin; sodium glucose cotransporter 2 inhibitor; teneligliptin; tofogliflozin; vildagliptin; antidiabetic agent; dipeptidyl peptidase IV inhibitor; glucagon like peptide 1 receptor, antihypertensive activity; arterial pressure; blood pressure monitoring; cardiovascular effect; human; meta analysis (topic); pathophysiology; priority journal; randomized controlled trial (topic); Review; animal; blood pressure; drug effect; hypertension; non insulin dependent diabetes mellitus; pharmacology, Animals; Arterial Pressure; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypertension; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors
DOI:
10.1007/s40256-020-00423-z
